drugset / Trial / NCT00628095
Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate
RandomizedParallel-groupQuadruple-blindTreatment
Summary
CE-224,535 is known to block a chemical that acts as a gateway to some of your immune cells. Blocking this gateway prevents the cells from pushing out 2 chemicals called IL-1 and IL-18 that are known to cause some of the inflammation seen in rheumatoid arthritis. It is hoped that taking this drug will reduce the symptoms of rheumatoid arthritis
Timeline
- Start
- 2008-04-07
- Primary completion
- 2009-02-04
- Completion
- 2009-02-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CE-224,535 | Small molecule | 500 mg | Oral |